期刊文献+

YAP2蛋白在涎腺腺样囊性癌组织及细胞中的表达 被引量:3

Role of EGFR on Expression of YAP2 in Salivary Adenoid Cystic Carcinoma
下载PDF
导出
摘要 目的:观察YAP2蛋白在涎腺腺样囊性癌组织及细胞中的表达。方法:通过免疫组织化学法检测YAP2蛋白在涎腺腺样囊性癌组织及细胞中的表达,用Western印迹法检测表皮生长因子受体(epidermal growth factor receptor,EGFR)对涎腺腺样囊性癌(salivary gland adenoid cystic carcinoma,SACC)SACC-83细胞YAP2蛋白的抑制。结果 :SACC组织中YAP2蛋白在肿瘤细胞胞质中阳性表达,正常腺体中YAP2蛋白主要表达在部分导管上皮中,两组相比差异有统计学意义(P<0.05)。免疫细胞化学染色结果显示SACC-83中YAP2蛋白阳性表达,加入EGFR蛋白后,SACC-83中YAP2蛋白表达有所降低。Western印迹法结果显示,不同质量浓度的EGFR蛋白(5、10、20、40μg/L)对SACC-83细胞YAP2蛋白的表达都有一定抑制作用,其中40μg/L质量浓度组抑制作用最明显。结论:YAP2蛋白在涎腺腺样囊性癌组织及细胞中高表达,EGFR蛋白对YAP2蛋白在SACC-83中表达有抑制作用。 Objective: This study aimed to observe the expression of YAP2 in salivary gland adenoid cystic carcinoma tissue and cell line. Methods: YAP2 protein in salivary gland adenoid cystic carcinoma tissue and cells were identified by immunohistochemistry with a muhiclonal antibody. EGFR inhibition of YAP2 in SACC-83 cells was detected by western blotting. Results: In SACC, positive expression of YAP2 were in the cytoplasm. In normal salivary gland, YAP2 positive were identified in some duct epithelia. There was statistical significance between them (P〈0.05). Expression of YAP2 protein in SACC-83 was down-regulated by the addition of EGFR. Western blot analysis showed EGFR(5, 10, 20, 40 p,g/L) inhibited the expression of YAP2 in SACC-83, and 40 p,g/L was most effective. Conclusion: YAP2 protein is overexpressed in salivary gland adenoid cystic carcinoma tissue and cells. EGFR protein inhibits the expression of YAP2 in the SACC-83.
出处 《口腔颌面外科杂志》 CAS 2013年第5期357-360,共4页 Journal of Oral and Maxillofacial Surgery
基金 黑龙江省教育厅科学技术研究资助项目(11541196)
关键词 YAP2 涎腺腺样囊性癌 SACC-83 表皮生长因子受体 YAP2 SACC SACC-83 EGFR
  • 相关文献

参考文献9

  • 1Liu J, Shao C, Tan ML, et al. Molecular biology of adenoid cystic carcinoma [J]. Head Neck, 2012, 34(11): 1665-1677.
  • 2Liu AM, Wong KF, Jiang X, et al. Regulators of mammalian Hippo pathway in cancer[J]. Biochim Biophys Acta, 2012, 1826(2):357-364.
  • 3Fan R, Kim NG, Gumbiner BM. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-l[J]. Proc Natl Acad Sci U S A, 2013, 110(7):2569-2574.
  • 4Hiemer SE, Varelas X. Stem cell regulation by the Hippo pathway [J]. Biochim Biophys Acta, 2013, 1830(2):2323- 2334.
  • 5Barry ER, Camargo FD. The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development [J]. Curr Opin Cell Biol, 2013, 25(2):247-253.
  • 6Yuan S, Yu SL, Chen HY, et ah Clustered genomic alterations in chromosome 7P dictate outcomes and targeted treatment responses of lung adenolarcinoma with EGFR-activating mutations [J]. J Clin Oncol, 201129(25): 3435-3442.
  • 7Antonieelli A, Cafarotti S, Indini A, et al. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation [J]. Int J Med Sci, 2013, 10(3):320- 330.
  • 8郭伟.晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J].口腔颌面外科杂志,2012,22(2):77-81. 被引量:12
  • 9马捷,张志愿.表皮生长因子受体拮抗剂治疗头颈部癌的进展[J].口腔颌面外科杂志,2011,21(2):142-146. 被引量:3

二级参考文献55

  • 1Ciardiello F,Tortom G.EGFR antagonists in cancer treatment[J].N Engl J Med,2008,358(11):1160-1174.
  • 2Hilger RA,Scheulen ME,Strumberg D.The Ras-Raf-MEK-ERK pathway in the treatment of cancer[J].Onkologie,2002,25(6):511-518.
  • 3Fresno Vara JA,Casado E,de Castro J,et al.P13K/Akt signalling pathway and cancer[J].Cancer Treat Rev,2004,30(2):193-204.
  • 4Akimoto T,Hunter NR,Buchmiilar L,et al.Inverse relationship between epidermal growth factor receptor expression and radiecurability of murine carcinomas[J].Clin Cancer Res,1999,5(1O):2884-2890.
  • 5Bonner JA,Harari PM,Giralt J,et al.Radiotherapy plus cetuximab for squamous eell carcinoma of the head and neck[J].N Engl J Med,2006,354(6):567-578.
  • 6Posner MR,wirth LJ.Cetuximab and radiotherapy for head and neck cancer[J].N Engl J Med,2006,354(6):634-636.
  • 7Vermorken JB,Mesia R,Rivera F,et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer[J].N Engl J Med,2008,359(11):1116-1127.
  • 8Burtness B,Goldwasser MA,Flood W,et al.Phase Ⅲ randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer:an Eastern Cooperative Oncology Group Study[J].J Clin Oncol,2005,23(34):8646-8654.
  • 9Cohen EE,Rosen F,Stadler WM,et al.Phase Ⅱ trial of ZD1839 in recurrent or metastatic 8qnamoug cell carcinoma of the head and neck[J].J Clin Oncol,2003,21(10):1980-1987.
  • 10Cohen EE,Kane MA,List MA,et al.Phase Ⅱ trial of gefitinib 250 rag daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck[J].Clin Cancer Res,2005,11(23):8418-8424.

共引文献13

同被引文献22

  • 1孙沫逸,王磊,杨连甲,侯锐,孙文斌,卢超.NGF在涎腺腺样囊性癌中的表达及与嗜神经侵袭和疼痛的关系[J].第四军医大学学报,2004,25(11):1012-1014. 被引量:30
  • 2谷建琦,张英怀,张杰英,蒋崇槟,杨威,贾志宇.转化生长因子α及其受体在腺样囊性癌中的表达及相互关系[J].现代口腔医学杂志,2007,21(1):60-62. 被引量:3
  • 3Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.
  • 4Huang J,Wu S,Barrera J,et al.The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie,the Drosophila Homolog of YAP[J].Cell,2005,122(3):421-434.
  • 5Steinhardt AA,Gavved MF,Klein AP,et al.Expression of Yes-associated protein in common solid tumors[J].Hum Pathol,2008,39(11):1582-1589.
  • 6Zhao B,Ye X,Yu J,et al.TEAD mediates YAP-dependent gene induc-tion and growth control[J].Genes Dev,2008,22(14):1962-1971.
  • 7Zhao B,Li L,Lei Q,et al.The Hippo-YAP pathway in organ size control and tumorigenesis:an updated version[J].Genes Dev,2010,24(9):862-74.
  • 8Liu AM,Poon RT,Luk JM.Microrna-375 targets hippo-signaling effector YAP in liver cancer and inhibits tumor properties[J].Biochem Biophys Res Commun,2010,394(3):623-627.
  • 9Yuan M,Tomlinson V,Lara R,et al.Yes-associated protein(YAP)functions as a tumor suppressor in breast[J].Cell Death Differ,2008,15(11):1752-1759.
  • 10栾修文,艾伟健,刘曙光,周会喜,曾曙光,王治平,李志强.游离皮瓣修复舌癌术后缺损联合语音训练的语音功能评价[J].广东牙病防治,2009,17(12):577-579. 被引量:13

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部